#PulmCC Physician Scientist @uabmedicine| Director @ UAB-ILD program #curePF|@HarvardChanSPH alum|Wife and Triplet Mom #womeninmedicine| Tweets are mine.
Birmingham, AL
Joined November 2015
- Tweets885
- Following610
- Followers771
- Likes4.2K
Tejaswini Kulkarni retweeted
This is a wonderful recognition for CRISPR! Congrats to all the innovators for all these groundbreaking inventions.
We’re proud to share that we’ve been named on the @TIME Best Inventions of 2024 list! This list recognizes a wide variety of new products, software or services that are making a difference in the world. #TIMEBestInventions
Tejaswini Kulkarni retweeted
#CHEST2024 Recap: Experts discussed how to evaluate and manage clinical worsening in patients with PH-ILD.
Read more in CHEST Daily News: hubs.la/Q02VyD6P0
Our @AnnalsATS paper exploring factors associated with persistence of antifibrotic therapies among patients with IPF enrolled in @PFFORG registry is now in press; underscores the importance of addressing mental health. #curePF @ahajaricase @UABPulmonary
Tejaswini Kulkarni retweeted
Great talk at #ICLAF2024 by Prof Kulkarni
on phase 3 clinical trials in Pulmonary Fibrosis - provides insight on failure - hope for success
👏🏼👏🏼👏🏼@tkulkarn1 👏🏼👏🏼🙏🏼
Lessons learnt, cautious optimism and moving forward in clinical trials in ILD - #ICLAF2024
This quoted post is unavailable.
Excellent panel discussing disparities and environmental exposures in ILDs - #ICLAF2024 #CurePF
#ICLAF2024 kicking off with patient experience session and looking forward to 5 days of advances towards #curePF
Tejaswini Kulkarni retweeted
Excellent discussion on early initiation of anti-fibrotic therapy in Non-IPF fibrotic lung disease, led by @tkulkarn1 and Dr. Danoff.
Should our primary emphasis be on enhancing QoL? Active involvement of patients in decision-making processes is key!
#CHEST2024 #CHESTTrainees
Tejaswini Kulkarni retweeted
Join us for journal club Thursday, October 3rd, 10 am EST on "Microscopic Small Airway Abnormalities Identified in Early Idiopathic Pulmonary Fibrosis In Vivo Using Endobronchial Optical Coherence Tomography"
Register here: thoracic.zoom.us/meeting/reg…
Tejaswini Kulkarni retweeted
Wow! Boehringer-Ingelheim announces that Nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study - a decade after the first positive phase III trials for IPF. Cannot wait to see the full results but this EXCITING !!!
#CureIPF
boehringer-ingelheim.com/us/…
Tejaswini Kulkarni retweeted
To commemorate Pulmonary Fibrosis Awareness Month, we will be sharing brilliant Pulmonary Fibrosis research from Thorax over the last year #CurePF
This paper highlights the innovative REMAP-ILD concept for drug development in fibrotic ILDs @leticiakawano @IPFdoc
thorax.bmj.com/content/79/8/…
In clinical practice,there are often questions about approach to positive antibodies in the absence clinical signs of SARD. This study shows that IPF disease course and response to Pirfenidone did not differ by autoantibody status #CurePF @cnewto
Dr. Tejaswini Kulkarni (@tkulkarn1) and researchers at @UABPulmonary evaluated the association of antinuclear #antibodies, #rheumatoid factor, and 💊 treatment outcomes of patients with #IPF from the 🩺 Phase III ASCEND trial.
@Pulmonary_Ther | bit.ly/3LPBsHp
Tejaswini Kulkarni retweeted
Telomere length testing is a readily available clinical test for precision management of ILD. We describe the clinical impact of TL testing in ILD clinic including impact on pharmacologic management and genetic testing @journal_CHEST
journal.chestnet.org/article…
A great discussion on the methodology of these upcoming guidelines and key take away points on management of patients with SARD-ILD - #curePF #CHEST_ILDTx @accpchest @ATSCPAssembly @PFFORG
A Review of ACR/CHEST Clinical Practice Guidelines on Treatment of ILD With Systemic Autoimmune Rheumatic Diseases
Watch the full webinar by the Diffuse Lung Disease and Lung Transplant Network: hubs.la/Q02ybG280
#MedEd #MedTwitter #CHEST_ILDTx
Tejaswini Kulkarni retweeted
Prof. Athol Wells presents elegant data from a recent multinational Delphi consensus that:
• Progression of ILD is progression irrespective of time since diagnosis
•“despite usual management” should be included in PPF definition
Important for future PPF guidelines.
#ATS2024
Tejaswini Kulkarni retweeted
Moments like this makes it worth coming to #ATS2024
…and a whole lot of good cheer with friends from all around the globe 🌏!!!
#LearningFromTheBest
#ATS2024
#MTWC
Tejaswini Kulkarni retweeted
Now please meet SUPER #ValerieQuinn, @REMAP_ILD project manager 🤩
Valerie rocks BIG TIME, you have no idea! Thanks, Valerie for your dedication to #REMAPILD!
I am so happy to meet you in person for the first time!
Ping @IPFdoc @tkulkarn1 @KerriBerriKerri
Tejaswini Kulkarni retweeted
…and a whole lot of good cheer with friends from all around the globe 🌏!!!
#LearningFromTheBest
#ATS2024
#MTWC
Excellent discussions on the potential applications of AI-driven tools in management of patients with PF- much more to be done to change the landscape to meet criteria for meaningful endpoint! #curePF
💡Poster Discussion Session: 🤖 Machine learned: AI-driven solutions in #ILD and 🫁 transplant!
Where: Room 33A-C
🕰️ 9:15 AM
Moderators: @tkulkarn1 , @SteveMHumphries & @andreaohMD
#ATS2024
@atscommunity @ATS_Assemblies
Tejaswini Kulkarni retweeted
#ATS2024 has been amazing!!! 🫁
Spectacular science and delightful mealtime research conversations with colleagues from all around the world about overcoming #PulmonaryFibrosis.
#FantasticSanDiego
#MakingProgressAtAllTimes
